Five-year Survival Analysis of a Cohort of Hepatocellular Carcinoma Patients Who Treated at the National Cancer Center, Korea

Park, Kyung Woo; Park, Joong-Won; Kim, Tae Hyun; Choi, Jun Il; Kim, Seong Hoon; Park, Hong Suk; Park, Sang Jae; Lee, Woojin; Shin, Hae Lim; Kim, Chang Min

doi:10.3350/kjhep.2007.13.4.530

Cited by 13 publications

(21 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, curable HCC for resection and local ablation accounts for .60% in Japan, in contrast to 30% in Western countries (4). The recent 5-year survival of all HCC patients (n ¼ 88 590) was 39.3% in Japan (5), 23.9% in Korea (30) and 13% …”

Section: Surveillance and Early Diagnosis Of Hccmentioning

confidence: 99%

Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective

Takayasu

2012

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Transcatheter arterial chemoembolization has been performed worldwide for patients with unresectable hepatocellular carcinoma for three decades. After long controversy, survival benefit was revealed by two randomized controlled trials. In Japan, chemoembolization accounted for initial treatment of 32% of patients and 58% for recurrent foci. The indications of chemoembolization are various: they are multinodular tumors in the Barcelona Clinic Liver Cancer staging system and two or three tumors .3 cm or four or more tumors in the Japanese guidelines, and both indications fulfill the Child-Pugh Class A/B or liver damage A/B and exclusion of vascular invasion or extrahepatic spread. Recently, both guidelines were identified to have almost similar content. The 4966 patients stratified to chemoembolization recommended by the Japanese guidelines showed that 3-year survival of patients with two or three tumors .3 cm or four or more tumors was 55 and 46% in Child-Pugh A, respectively, and 30 and 22% in Class B, respectively. These results would help in comparing the outcome of chemoembolization in the different backgrounds of the East and West. The modified Response Evaluation Criteria in Solid Tumor guideline is now proposed to cover the deficiency of Response Evaluation Criteria in Solid Tumor to evaluate the response to chemoembolization. Recently, chemoembolization with drug-eluting beads and radioembolization with yttrium-90 microspheres have been introduced, and each of them showed similar tumor response and median survival compared with conventional chemoembolization. Moreover, the combination of chemoembolization and molecular targeted agent is now ongoing to evaluate the synergistic effect.

show abstract

Section: Surveillance and Early Diagnosis Of Hccmentioning

confidence: 99%

Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective

Takayasu

2012

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…The incidences of the remaining liver cancer types are much lower than these two mentioned above [4]. About 16,000 new patients got primary liver cancer in Korea in 2010 (11,818 males and 4,103 females), which accounted for 7.9% of the total cancers.…”

Section: Introductionmentioning

confidence: 95%

“…Among the liver cancers, primary hepatocellular carcinoma (defined as originating in the liver) has the highest frequency of occurrence among the adults [3]. For Korean patients, there have been a number of recent studies on analyzing the clinical features of hepatocellular carcinoma with respect to age [3] and 5-year survival [4,5]. In addition, there was a study about linking the prognosis of patients with hepatocellular carcinoma to the stage of their cancer [6].…”

Section: Introductionmentioning

confidence: 99%

Characteristics of Hepatocellular Carcinoma Patients According to Their Cancer Stage at the Time of Diagnosis in Korea

Lee¹,

Min²,

Park³

2016

IJBSBT

View full text Add to dashboard Cite

show abstract

“…In 10 patients, the procedure was performed without artificial pleural effusion. In 15 patients, the procedure was performed after injecting artificial pleural effusion fluid with normal saline, and the volume was on average 787 cm 3 (range 500-1000 cm 3 ).…”

Section: Transarterial Chemoembolisation Proceduresmentioning

confidence: 99%

“…Hepatocellular carcinoma (HCC) is the most frequent cancer among the primary liver cancers, accounting for approximately 75% of all the cases of liver cancer in the Republic of Korea. The prognosis of HCC is poor with a 5 year survival rate of approximately 23.9% [1][2][3]. The best treatment method for HCC is liver transplantation, but it is difficult to obtain a donor.…”

mentioning

confidence: 99%

Therapeutic effect of high-intensity focused ultrasound combined with transarterial chemoembolisation for hepatocellular carcinoma <5 cm: comparison with transarterial chemoembolisation monotherapy—preliminary observations

J¹,

Dj²,

Se³

et al. 2012

BJR

View full text Add to dashboard Cite

Objective: To retrospectively compare the therapeutic effects of combined highintensity focused ultrasound (HIFU) and transarterial chemoembolisation (TACE) with TACE alone for the treatment of non-advanced hepatocellular carcinomas (HCCs) ,5 cm. Methods: We retrospectively reviewed the tumour responses of 32 HCCs of 25 patients who underwent combined HIFU and TACE, and 46 HCCs of 32 patients who underwent TACE only. The mean follow-up observation of the TACE+HIFU group was on average 31 months and that of the TACE group was 33 months. Those patients who had undergone any other treatment modality (including systemic chemotherapy) during the follow-up observation period were excluded. The therapeutic effects were classified according to the modified Response

show abstract

Five-year Survival Analysis of a Cohort of Hepatocellular Carcinoma Patients Who Treated at the National Cancer Center, Korea

Abstract: This study presented, for the first time, the 5-YSRs of a cohort of HCC patients.

Cited by 13 publications

References 18 publications

Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective

Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective

Characteristics of Hepatocellular Carcinoma Patients According to Their Cancer Stage at the Time of Diagnosis in Korea

Therapeutic effect of high-intensity focused ultrasound combined with transarterial chemoembolisation for hepatocellular carcinoma <5 cm: comparison with transarterial chemoembolisation monotherapy—preliminary observations

Contact Info

Product

Resources

About